Zobrazeno 21 - 30
of 51
pro vyhledávání: '"María González Cao"'
Autor:
Ignacio Rodríguez García, María González Cao, Sonia Baulies Caballero, Francisco Tresserra Casas, Rafael Fábregas Xaudaró, Carmen Ara Pérez, Maite Cusidó Gimferrer, Nadwa Kanjou Augé, Belén Úbeda Hernández
Publikováno v:
Revista de Senología y Patología Mamaria. 26:11-17
Resumen Objetivos La quimioterapia neoadyuvante (QNA) es el tratamiento de eleccion en las pacientes con cancer de mama localmente avanzado. El objetivo de este estudio es evaluar la utilidad de QNA en tumores pequenos pero con factores pronosticos d
Publikováno v:
Translational lung cancer research. 4(6)
One of the main hallmarks of cancer is the capability of evading immune destruction. In order to drive tumor progression, malignant cells are able to promote immunosuppressive mechanisms avoiding recognition and elimination. Increasing knowledge of t
Autor:
María, González-Cao
Publikováno v:
Translational lung cancer research. 4(6)
Autor:
Miguel A, Molina-Vila, Clara Mayo, de-Las-Casas, Jordi, Bertran-Alamillo, Nuria, Jordana-Ariza, María, González-Cao, Rafael, Rosell
Publikováno v:
Annals of translational medicine. 3(20)
Testing of tumor tissue remains the recommended method for detecting the presence of somatic mutations in human malignancies. V600E is the most frequent somatic point mutation in metastatic melanoma, providing a unique molecular marker for this malig
Autor:
Ivan, Márquez-Rodas, Pablo, Cerezuela, Ainara, Soria, Alfonso, Berrocal, Aldo, Riso, María, González-Cao, Salvador, Martín-Algarra
Publikováno v:
Annals of translational medicine. 3(18)
In recent years, new strategies for treating melanoma have been introduced, improving the outlook for this challenging disease. One of the most important advances has been the development of immunotherapy. The better understanding of the role of the
Publikováno v:
Journal of Computer Assisted Tomography. 29:756-759
Carcinoid tumors are associated with the production of a number of bioactive substances that might deposit on the endocardium (endocardial fibroelastosis) and produce cardiac failure. Carcinoid heart disease usually presents as right-sided valvular h
Autor:
Rafael, Rosell, Niki, Karachaliou, Daniela, Morales-Espinosa, Carlota, Costa, Miguel Angel, Molina, Irene, Sansano, Amaya, Gasco, Santiago, Viteri, Bartomeu, Massuti, Jia, Wei, María, González Cao, Alejandro, Martínez Bueno
Publikováno v:
Translational lung cancer research. 2(3)
It is widely acknowledged that there is a need for molecular profiling in non-small-cell lung cancer. For example, treatment based on EGFR mutation status has attained successful results. However, in spite of excellent initial response to oral EGFR t
Autor:
Marta Vives-Usano, Beatriz García Pelaez, Ruth Román Lladó, Mónica Garzón Ibañez, Erika Aldeguer, Sonia Rodriguez, Andrés Aguilar, Francesc Pons, Santiago Viteri, Carlos Cabrera, Maria José Catalán, Irene Moya, María Gonzalez Cao, Juan José García-Mosquera, Alejandro Martinez-Bueno, Ekaterina Meshoulam, Nuria Jordana, Laura Berrocal, Rafael Rosell, Miguel Angel Molina, Clara Mayo de las Casas
Publikováno v:
Journal of Molecular Pathology, Vol 2, Iss 2, Pp 123-134 (2021)
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the
Externí odkaz:
https://doaj.org/article/ca772e98c22442f8b9bdad5c2f30d92d
Autor:
Marcelo Sánchez, Susana Puig, Joseph Malvehy, Marta Martin, Pere Gascón, Begoña Mellado, Rosa M. Martí, Teresa Castel, Joseph Herrero, María González Cao, Cristina Carrera, Carlos Conill
Publikováno v:
Melanoma research. 16(1)
The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma. Treatment consisted of temozolomide (150 mg/m per
Autor:
Marcelo Sánchez, Pere Gascón, Josep Eugeni Herrero, Carlos Conill, Begoña Mellado, Josep Malvehy, Teresa Castel, María González Cao, Rosa M. Martí, Susana Puig
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 7(6)
Metastatic melanoma has an ominous prognosis. Bio-chemotherapy regimens can increase the response rate but with a high degree of toxicity due, mainly, to the use of high-dose intravenous interleukin-2. To test the feasibility and activity profile of